BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18463144)

  • 1. Use of rituximab for the treatment of rheumatoid arthritis: the Latin American context.
    Soriano ER; Galarza-Maldonado C; Cardiel MH; Pons-Estel BA; Massardo L; Caballero-Uribe CV; Achurra-Castillo AF; Barile-Fabris LA; Chávez-Corrales J; Díaz-Coto JF; Esteva-Spinetti MH; Guibert-Toledano M; Palazuelos FI; Keiserman MW; Lomonte AV; Mota LM; Pineda Villaseñor C; Alarcón GS;
    Rheumatology (Oxford); 2008 Jul; 47(7):1097-9. PubMed ID: 18463144
    [No Abstract]   [Full Text] [Related]  

  • 2. [Guidelines for usage of biological agents for treatment of rheumatoid arthritis].
    Takeuchi T
    Nihon Rinsho; 2005 Jan; 63 Suppl 1():444-7. PubMed ID: 15799396
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.
    Teng YK; Tekstra J; Breedveld FC; Lafeber F; Bijlsma JW; van Laar JM
    Ann Rheum Dis; 2009 Jun; 68(6):1075-7. PubMed ID: 19435725
    [No Abstract]   [Full Text] [Related]  

  • 4. How to dose infliximab in rheumatoid arthritis: new data on a serious issue.
    van Vollenhoven RF
    Ann Rheum Dis; 2009 Aug; 68(8):1237-9. PubMed ID: 19605741
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab (Rituxan) for rheumatoid arthritis.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):34-5. PubMed ID: 16625143
    [No Abstract]   [Full Text] [Related]  

  • 6. [Experiences with infliximab in the treatment of active rheumatoid arthritis and spondyloarthropathy].
    Dahlin J; Sørensen SF
    Ugeskr Laeger; 2003 Nov; 165(48):4646-9. PubMed ID: 14677464
    [No Abstract]   [Full Text] [Related]  

  • 7. [Administration of rituximab in rheumatoid arthritis from the position of evidence-based medicine].
    Nasonov EL
    Ter Arkh; 2007; 79(12):76-82. PubMed ID: 18220039
    [No Abstract]   [Full Text] [Related]  

  • 8. [Rituximab (MabThera) as treatment of active rheumatoid arthritis].
    El Fassi D; Nielsen CH; Bendtzen K
    Ugeskr Laeger; 2006 Nov; 168(47):4079-81. PubMed ID: 17134602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
    Kerkeni S; Marotte H; Miossec P
    Muscle Nerve; 2008 Oct; 38(4):1343-5. PubMed ID: 18816604
    [No Abstract]   [Full Text] [Related]  

  • 10. Timing of DAS28 in infliximab therapy.
    Armstrong DJ; Bruce IN
    Rheumatology (Oxford); 2005 Sep; 44(9):1203-4; author reply 1204. PubMed ID: 15870143
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab for rheumatoid arthritis. Practical guidance for optimizing treatment.
    Furfaro N
    Adv Nurse Pract; 2008 Jan; 16(1):61-4. PubMed ID: 20014746
    [No Abstract]   [Full Text] [Related]  

  • 12. Infusion reaction to infliximab in a patient with rheumatoid arthritis after discontinuation over 1 year and readministration.
    Toki H; Momohara S; Tsukahara S; Ikari K
    J Rheumatol; 2008 Sep; 35(9):1896-7; author reply 1897. PubMed ID: 18785300
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term treatment of rheumatoid arthritis with tumour necrosis factor alpha blockade: outcome of ceasing and restarting biologicals.
    Buch MH; Marzo-Ortega H; Bingham SJ; Emery P
    Rheumatology (Oxford); 2004 Feb; 43(2):243-4. PubMed ID: 14739466
    [No Abstract]   [Full Text] [Related]  

  • 14. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
    Renato GM
    Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate.
    Owczarczyk K; Hellmann M; Fliedner G; Röhrs T; Maizus K; Passon D; Hallek M; Rubbert A
    Ann Rheum Dis; 2008 Nov; 67(11):1648-9. PubMed ID: 18854518
    [No Abstract]   [Full Text] [Related]  

  • 16. [Rituximab (Mabthera)--new approach in treatment of rheumatoid arthritis].
    Anić B
    Reumatizam; 2007; 54(2):72-3. PubMed ID: 18351146
    [No Abstract]   [Full Text] [Related]  

  • 17. [Administration of monoclonal antibodies to B-lymphocytes (rituximab) in rheumatoid arthritis in Russia].
    Nasonov EL; Lukina GV; Sigidin IaA; Bazevich LA; Zlobina TI; Kamalova RG; Kniazeva LA; Mazurov VI; Men'shikova LV; Sizikov AE; Smirnova EA; Fofonova NA; Shabalina TV; Shkil' NV; Iakushin SS
    Ter Arkh; 2008; 80(8):57-62. PubMed ID: 18807543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shortening infusion times for infliximab administration.
    Buch MH; Bryer D; Lindsay S; Rees-Evans B; Fairclough A; Emery P
    Rheumatology (Oxford); 2006 Apr; 45(4):485-6. PubMed ID: 16352636
    [No Abstract]   [Full Text] [Related]  

  • 19. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 20. Tocilizumab for rheumatoid arthritis.
    Drug Ther Bull; 2010 Jan; 48(1):9-12. PubMed ID: 20040568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.